155 related articles for article (PubMed ID: 37236354)
1. Testosterone Treatment of Men with Unequivocal Hypogonadism Following Treatment of Organ-Confined Prostate Cancer.
Jones RB; Snyder PJ
Endocr Pract; 2023 Sep; 29(9):723-726. PubMed ID: 37236354
[TBL] [Abstract][Full Text] [Related]
2. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.
Pastuszak AW; Pearlman AM; Lai WS; Godoy G; Sathyamoorthy K; Liu JS; Miles BJ; Lipshultz LI; Khera M
J Urol; 2013 Aug; 190(2):639-44. PubMed ID: 23395803
[TBL] [Abstract][Full Text] [Related]
3. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.
Kaufman JM; Graydon RJ
J Urol; 2004 Sep; 172(3):920-2. PubMed ID: 15310998
[TBL] [Abstract][Full Text] [Related]
4. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
Sarosdy MF
Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
6. Testosterone replacement therapy after primary treatment for prostate cancer.
Agarwal PK; Oefelein MG
J Urol; 2005 Feb; 173(2):533-6. PubMed ID: 15643240
[TBL] [Abstract][Full Text] [Related]
7. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
Rhoden EL; Morgentaler A
J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
[TBL] [Abstract][Full Text] [Related]
8. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
10. The role of testosterone replacement therapy following radical prostatectomy.
Khera M; Lipshultz LI
Urol Clin North Am; 2007 Nov; 34(4):549-53, vi. PubMed ID: 17983894
[TBL] [Abstract][Full Text] [Related]
11. Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial.
Cunningham GR; Ellenberg SS; Bhasin S; Matsumoto AM; Parsons JK; Preston P; Cauley JA; Gill TM; Swerdloff RS; Wang C; Ensrud KE; Lewis CE; Pahor M; Crandall JP; Molitch ME; Cifelli D; Basaria S; Diem SJ; Stephens-Shields AJ; Hou X; Snyder PJ
J Clin Endocrinol Metab; 2019 Dec; 104(12):6238-6246. PubMed ID: 31504596
[TBL] [Abstract][Full Text] [Related]
12. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.
Bhasin S; Travison TG; Pencina KM; O'Leary M; Cunningham GR; Lincoff AM; Nissen SE; Lucia MS; Preston MA; Khera M; Khan N; Snabes MC; Li X; Tangen CM; Buhr KA; Thompson IM
JAMA Netw Open; 2023 Dec; 6(12):e2348692. PubMed ID: 38150256
[TBL] [Abstract][Full Text] [Related]
13. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
[TBL] [Abstract][Full Text] [Related]
14. Effects of testosterone replacement in hypogonadal men.
Snyder PJ; Peachey H; Berlin JA; Hannoush P; Haddad G; Dlewati A; Santanna J; Loh L; Lenrow DA; Holmes JH; Kapoor SC; Atkinson LE; Strom BL
J Clin Endocrinol Metab; 2000 Aug; 85(8):2670-7. PubMed ID: 10946864
[TBL] [Abstract][Full Text] [Related]
15. Testosterone supplementation does not worsen lower urinary tract symptoms.
Pearl JA; Berhanu D; François N; Masson P; Zargaroff S; Cashy J; McVary KT
J Urol; 2013 Nov; 190(5):1828-33. PubMed ID: 23764078
[TBL] [Abstract][Full Text] [Related]
16. Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer.
Pastuszak AW; Khanna A; Badhiwala N; Morgentaler A; Hult M; Conners WP; Sarosdy MF; Yang C; Carrion R; Lipshultz LI; Khera M
J Urol; 2015 Nov; 194(5):1271-6. PubMed ID: 26025500
[TBL] [Abstract][Full Text] [Related]
17. Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends.
Kaplan AL; Trinh QD; Sun M; Carter SC; Nguyen PL; Shih YT; Marks LS; Hu JC
J Sex Med; 2014 Apr; 11(4):1063-1070. PubMed ID: 24443943
[TBL] [Abstract][Full Text] [Related]
18. Racial differences in hypogonadal improvement and prostate-specific antigen levels in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
Int Braz J Urol; 2010; 36(6):700-7; discussion 707-9. PubMed ID: 21176276
[TBL] [Abstract][Full Text] [Related]
19. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer.
Guay AT; Perez JB; Fitaihi WA; Vereb M
Endocr Pract; 2000; 6(2):132-8. PubMed ID: 11421528
[TBL] [Abstract][Full Text] [Related]
20. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
Page ST; Hirano L; Gilchriest J; Dighe M; Amory JK; Marck BT; Matsumoto AM
J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]